(Q45974065)

18 December 2017

title

Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. (English)

1 reference

18 December 2017

1 reference

H-D Yoo

1

1 reference

18 December 2017

S-A Park

series ordinal

2

1 reference

18 December 2017

H-Y Cho

series ordinal

3

1 reference

18 December 2017

Y-B Lee

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

10 June 2009

1 reference

18 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

18 December 2017

volume

86

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

281-284

1 reference

18 December 2017

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Effects of CYP3A inhibition on the metabolism of cilostazol

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.90

1 reference

18 December 2017

Dimensions Publication ID

1022858277

0 references

1 reference

18 December 2017